
    
      A single arm, prospective, multicenter, non-randomized, open trial, up to 5 Years follow-up
      with the Symetis ACURATE TFâ„¢ Transfemoral Aortic Bioprosthesis for minimal invasive
      implantation via transfemoral access to treat patients with severe aortic stenosis where
      conventional aortic valve replacement (AVR) via open heart surgery is considered to be
      associated with high risk.
    
  